10005 Muirlands Boulevard
Suite G, First Floor
196 articles with ChromaDex, Inc.
ChromaDex Corp. announced that it will hold a conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2021.
ChromaDex Corp. announced the results of four recently published preclinical studies, highlighting new findings for its patented nicotinamide riboside healthy aging nutrient.
Tru Niagen® Revenue for the Three-Month Period Ended March 31, 2021 Totals $12.4 Million, up 12% Year-over-Year, with Total Company Revenue of $14.7 Million and Gross Margin of 62.9%.
ChromaDex Corp. announced that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology company.
ChromaDex Corp. is scheduled to participate in a virtual presentation at the Benzinga Small Cap Conference on Thursday, May 13, 2021 at 11:30am ET.
H&H Group expands Swisse® healthy aging product line into growing NAD+ space with Niagen® from ChromaDex
Karam has spent his career driving consumer businesses across multiple geographies and cultures, including scaling direct-to-consumer operations across digital, social, and traditional marketing platforms, as well as launching and scaling product innovation.
ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency
ChromaDex External Research Program (CERP) and the Citrin Foundation to collaborate on series of studies exploring rare disease citrullinemia
ChromaDex Corp. announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Lytham Partners Spring 2021 Investor Conference.
ChromaDex Corp. announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Zooming with LD investor conference.
Revenue for the Three-Month Period Ended December 31, 2020 Totals $15.4 Million, up 18% Year-over-Year, with Gross Margin of 61.0%, and Lower Operating Expenses.
ChromaDex to Present at Oppenheimer 31 st Annual Healthcare Conference
ChromaDex Corp. (NASDAQ: CDXC) announced today that it has entered into a securities purchase agreement for the sale of $25.0 million of its common stock in a private placement. The private placement was led by a new international investor and is expected to close on or about February 23, 2021, subject to the satisfaction of customary closing conditions.
ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the December 2020 Benzinga Small Cap Conference on Wednesday, December 9, 2020 at 11:15am ET (8:15am PT). This inaugural Small Cap Conference is a day dedicated to bridging the gap between Small Cap companies, investors and traders. The event will have multiple days of networking and education in a virtual setting. A webcast of the pr
ChromaDex Announces New Clinical Trial to Investigate Niagen® and Milk Production Among Mothers in the Neonatal Intensive Care Unit (NICU)
Researchers to compare milk production among mothers of preterm infants while receiving ChromaDex’s ingredient nicotinamide riboside (Niagen®, or NR)
ChromaDex and Watsons Launch New TRU NIAGEN® EX Stick Packs in Hong Kong, Expanding Product Line and Advancing Global Retail Partnership
ChromaDex and Watsons Hong Kong launch new TRU NIAGEN® EX stick packs for on-the-go consumers in new delivery method
ChromaDex Corp. announced that it will hold a conference call on Wed., November 4, 2020 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2020.
New Study from NIH Finds Nicotinamide Riboside Helps Improve Telomere Dysfunction in Human Cells, Mice
New preclinical study finds boosting NAD+ with nicotinamide riboside alleviated telomere damage, providing protective effect to DNA strands
Nestlé Health Science launches Celltrient™ products to help fight key drivers of cell aging featuring ChromaDex’s flagship ingredient Tru Niagen®
10/12/2020It was a moderately busy week for clinical trial news. Here’s a look.